Bupi Yishen Formula Versus Losartan for Non-Diabetic Stage 4 Chronic Kidney Disease: A Randomized Controlled Trial

• Main Authors: Wei Mao (Author), Nizhi Yang (Author), Lei Zhang (Author), Chuang Li (Author), Yifan Wu (Author), Wenwei Ouyang (Author), Peng Xu (Author), Chuan Zou (Author), Chunpeng Pei (Author), Wei Shi (Author), Jihong Zhan (Author), Hongtao Yang (Author), Hongyu Chen (Author), Xiaoqin Wang (Author), Yun Tian (Author), Fang Yuan (Author), Wei Sun (Author), Guoliang Xiong (Author), Ming Chen (Author), Jianguo Guan (Author), Shuifu Tang (Author), Chunyan Zhang (Author), Yuning Liu (Author), Yueyi Deng (Author), Qizhan Lin (Author), Fuhua Lu (Author), Weihong Hong (Author), Aicheng Yang (Author), Jingai Fang (Author), Jiazhen Rao (Author), Lixin Wang (Author), Kun Bao (Author), Feng Lin (Author), Yuan Xu (Author), Zhaoyu Lu (Author), Guobin Su (Author), La Zhang (Author), David W Johnson (Author), Daixin Zhao (Author), Haijing Hou (Author), Lizhe Fu (Author), Xinfeng Guo (Author), Lihong Yang (Author), Xindong Qin (Author), Zehuai Wen (Author), Xusheng Liu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Chinese herbal medicine (CHM) might have benefits in patients with non-diabetic chronic kidney disease (CKD), but there is a lack of high-quality evidence, especially in CKD4. This study aimed to assess the efficacy and safety of Bupi Yishen Formula (BYF) vs. losartan in patients with non-diabetic C...